[서울파이낸스 김현경 기자] Daewoong Pharmaceutical announced on the 25th that it has received approval from the Ministry of Food and Drug Safety for a phase 3 clinical trial plan for the prevention of Corona 19 for Hoy Star Tablet (ingredient name chamostat mesylate), which is being developed as a treatment for Corona 19.
In this clinical trial, the effect of Hoystar tablets on preventing COVID-19 infection in 1012 self-containers exposed to the Corona 19 virus is confirmed. Phase 3 clinical trials are conducted at Samsung Medical Center and Asan Medical Center, and administered to subjects in February.
Hoystar tablet is a specialty medicine used for chronic pancreatitis, and Daewoong Pharmaceutical is developing it as an edible type of COVID-19 treatment. Prior to this, Daewoong Pharmaceutical was approved for phase 2 and 3 clinical trials targeting mild corona19 patients and phase 3 clinical trials targeting severe patients.
The interim results of phase 2a clinical trials of Hoystar tablet administration to mild Corona 19 patients failed to achieve statistical significance. At the time, Daewoong Pharmaceutical said that the time it took for Corona 19 patients to convert to negative was not statistically significant, but said that it would continue development, claiming that the speed at which the virus was removed was faster than that of the placebo group.
Daewoong Pharmaceutical said, “Hoystar tablets are convenient to take orally and are expected to have the greatest effect in the initial process of the virus starting to replicate, and because it is predicted to respond to virus mutations, we provide the optimal treatment option to prevent the spread of Corona 19 infection. It is expected to provide.”
Copyright © Seoul Finance Unauthorized reproduction and redistribution prohibited